Maprotilin Neuraxpharm (Maprotiline Hydrochloride)

Maprotiline Hydrochloride is indicated for depressive disorders that involve norepinephrine dysregulation.

• Major depressive disorder: reduces core depressive symptoms and improves mood in adults.
• Dysthymia: alleviates persistent low‑grade depressive mood over long periods.
• Depressive disorder not otherwise specified: provides symptomatic relief in patients with depressive symptoms that do not meet full diagnostic criteria.

• Maprotiline Hydrochloride acts primarily as a selective norepinephrine reuptake inhibitor, blocking the norepinephrine transporter and increasing synaptic norepinephrine levels. It also exhibits antagonistic activity at certain serotonergic, histaminergic and cholinergic receptors, contributing to its overall antidepressant profile without directly stimulating serotonin reuptake.

Maprotiline Hydrochloride may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects

• Dry mouth: reduced salivation leading to throat discomfort.
• Drowsiness: increased sedation, especially at treatment initiation.
• Constipation: slowed gastrointestinal motility.
• Weight gain: gradual increase in body weight.
• Blurred vision: temporary visual disturbances.
• Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects

• Seizures: risk of convulsive episodes, particularly at high doses.
• Cardiac arrhythmia: irregular heart rhythms that may require monitoring.
• Severe hypotension: sudden drop in blood pressure causing faintness.
• Hepatotoxicity: liver enzyme elevations or liver injury.
• Agranulocytosis: marked reduction in white blood cells.
• Suicidal thoughts: emergence or worsening of suicidal ideation.

Before prescribing Maprotiline Hydrochloride, clinicians should consider several safety measures.

• Cardiac assessment: evaluate history of heart disease before initiating therapy.
• Mood monitoring: watch for worsening depression or emergence of suicidal thoughts.
• Discontinuation: avoid abrupt cessation to reduce risk of withdrawal symptoms.
• Hepatic function: use caution and adjust if severe liver impairment is present.
• Store at room temperature: keep in original container, protect from moisture and light.

Maprotiline Hydrochloride can interact with other medicines; interactions are categorized by clinical significance.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): concurrent use may cause hypertensive crisis.
• Other norepinephrine reuptake inhibitors: additive sympathomimetic effects.
• Tricyclic antidepressants: increased risk of cardiotoxicity and serotonin syndrome.
• Linezolid: potential for serotonin‑related adverse events.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: may enhance blood‑pressure‑lowering effect.
• CNS depressants (e.g., benzodiazepines): increased sedation.
• Anticholinergic drugs: heightened anticholinergic burden.